Diagnosis requires a combination of clinical performance, imaging, laboratory testing and pathological activation. The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of treatment plans for PF-ILD requires individualized development, usually including drug therapy, rehabilitation interventions, regular follow-up, and multidimensional management.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD-associated thrombocytoxin antibodies.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.